Pfizer discontinues Asian development of glaucoma compound

Article

Pfizer has announced that it does not plan to begin a Phase III trial of its experimental compound PF-03187207 for glaucoma and ocular hypertension in Asia.

Pfizer has announced that it does not plan to begin a Phase III trial of its experimental compound PF-03187207 for glaucoma and ocular hypertension in Asia. The move follows an announcement in May of this year that, following disappointing Phase II results, Pfizer was to discontinue development of the compound outside of Asia.

The dose-ranging Phase II study of the nitric oxide-donating prostaglandin analogue (developed in conjunction with NicOx SA) failed to achieve its primary endpoint of statistically significant clinical superiority over Xalatan (latanoprost; Pfizer), although PF-03187207 demonstrated better results than Xalatan in terms of diurnal intraocular pressure (IOP) reduction, and demonstrated good safety and tolerability profiles.

NicOx and Pfizer are currently holding discussions regarding the rights to the compound, and it is thought that any future research regarding nitric oxide-donating technology will concentrate on diabetic retinopathy.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.